Pharma Pledge Wave Now ~$500B: Reuters Tallies 17 Companies' US Commitments as BD Buys $19B of Device-Tariff Protection
Reuters' Oct 6 tally puts the pharma reshoring pledge wave at "roughly $500 billion in US investments" across Eli Lilly, Pfizer, AstraZeneca, Roche and peers — "as they seek to strengthen infrastructure, mitigate supply-chain risks and reassure investors." The named-project detail keeps accumulating: Pfizer $70B (R&D + manufacturing, with a tariff grace period), Lilly $27B across six US plants, J&J $55B over four years, Roche $50B + $550M diagnostics expansion, AstraZeneca $50B by 2030, Novartis $23B across 10 facilities, Sanofi $20B through 2030, Merck's $3B Virginia plant, Amgen's $900M Ohio expansion, BMS's $2.3B Houston site, Gilead $11B, CSL $1.5B, GSK $30B, AbbVie $100B (R&D).
Two fresh data points sharpen the "policy dollars vs. conversion" question this topic tracks:
- BD (Becton Dickinson) is buying tariff protection, not just capacity: per the Washington Post's Oct 6 Health Brief, BD is "investing $19 billion in the U.S. in exchange for protection from future medical device tariffs" — the first explicit quid-pro-quo of its kind, extending the Section 232 bargain from drugs to devices. The pledge wave is now partly a tariff-hedging instrument, which means some share of it was never incremental capex.
- The conversion test remains unanswered. The standing question — whether the
$480B/22-site pledge wave (44,000 jobs cited) converts into bioprocess equipment orders at 15%+ rates ($75B of bioreactor/filtration/single-use demand) — gets its next read at Thermo Fisher and Danaher Q3 earnings in late October. Nothing in this week's announcements changes the equipment-order picture; it's still pledges and groundbreaking photos, not order books.
Also notable: the CDMO channel is where foreign-domiciled capacity is landing without headline pledges — Alvotech selected LOTTE Biologics' Syracuse, NY plant (Oct 6) for US biosimilar drug substance, adding capacity at an existing site rather than announcing a new one.
The macro backdrop for all of this: fed funds at 3.75%, the 10-year at 5.22% (Oct 8), unemployment 4.2% — long money stays expensive for a $500B capex wave that is mostly unfunded pledges. See Pharma Pledge Wave Now ~$500B: Reuters Tallies 17 Companies' US Commitments as BD Buys $19B of Device-Tariff Protection for the Section 232 rate-ladder mechanics and US Manufacturing Construction: First Monthly Increase Since January — But Still Down ~19% YoY, and Data Centers Carry Everything for what's actually breaking ground economy-wide.